IMNM - NASDAQ
Immunome, Inc.
$19.78
-0.15%Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
At a Glance
Live Snapshotimnm
Operating Expenses
Last Annual Value
218.10M
3-Year CAGR
81%
5-Year CAGR
80%
10-Year CAGR
40%
Immunome, Inc. Competitors Analysis of Operating Expenses
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Immunome, Inc. NASDAQ:IMNM | 218.10M | 20.9% | 54.0% | N/A | |
 Zenas BioPharma, Inc. NASDAQ:ZBIO | 221.38M | 36.4% | N/A | N/A | |
 Intellia Therapeutics, Inc. NASDAQ:NTLA | 492.74M | -3.2% | 10.9% | 26.1% | |
 Upstream Bio, Inc. NASDAQ:UPB | 80.13M | 23.5% | N/A | N/A | |
 Maze Therapeutics, Inc. NASDAQ:MAZE | 140.50M | 12.5% | N/A | N/A | |
 Celldex Therapeutics, Inc. NASDAQ:CLDX | 288.90M | 88.1% | 66.5% | 7.5% | |
 Vera Therapeutics, Inc. NASDAQ:VERA | 315.47M | 45.7% | 55.8% | N/A | |
 Biohaven Ltd. NYSE:BHVN | 741.24M | 19.3% | 27.6% | N/A | |
 Spyre Therapeutics, Inc. NASDAQ:SYRE | 37.91M | -46.2% | -14.8% | 3.6% |
Immunome, Inc. Fair Value Envelope
Related Guides
Continue your IMNM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.